-
Stay Connected
Get the latest news on exciting speakers, workshops & learning opportunities at ISDE 2021.
Subscribe for Updates
Diseases of the oesophagus can be difficult to treat because medicines must pass quickly through a moist, muscular tube before reaching the affected tissue. A swallowed tablet may expose the whole body to a drug while delivering only a small proportion to an ulcer, tumour, stricture or inflamed segment. Novel drug delivery systems aim to improve contact time and concentrate treatment where it is needed.
This area was highly relevant to the scientific programme of the 17th World Congress for Esophageal Diseases, hosted virtually by the International Society for Diseases of the Esophagus in 2021. For clinicians and researchers in Australia, the subject also connects laboratory innovation with practical concerns such as long travel to specialist centres, Therapeutic Goods Administration requirements and access through a relatively small healthcare market.
| Delivery approach | How it works | Potential value | Main development concern |
|---|---|---|---|
| Mucoadhesive film or gel | Sticks to the oesophageal lining | Prolonged local exposure | Swallowing comfort and wash-off |
| Nanoparticles or lipid carriers | Encapsulate and release an active drug | Improved stability and cellular uptake | Manufacturing and safety assessment |
| Biodegradable stent coating | Releases medicine at a narrowed segment | Combines mechanical support with therapy | Migration, removal and dose control |
| pH- or enzyme-responsive system | Releases drug under selected conditions | More targeted activation | Variable disease conditions |
| Endoscopic depot or injection | Places formulation beside the lesion | High local concentration | Procedure-related risk and specialist skill |
Systemic treatment can produce unwanted effects when a drug circulates throughout the body. A local formulation may reduce exposure elsewhere, extend residence time and support lower doses. These advantages are particularly attractive for painful inflammation, reflux-related injury, Barrett’s-associated lesions and selected cancers.
The oesophagus presents a demanding target. Saliva, gravity, peristalsis and repeated swallowing can remove a formulation within minutes. A successful platform therefore needs to adhere without causing obstruction, resist dilution and release its payload at a predictable rate.
Mucoadhesive tablets, oral films, viscous liquids and hydrogels are among the most accessible approaches. Polymers such as chitosan, alginate and carbomers can be engineered to swell or adhere to mucosal surfaces. A formulation might carry an anti-inflammatory, antimicrobial or cytoprotective agent directly to damaged tissue.
Nanocarriers provide another route. Liposomes, polymeric nanoparticles and solid lipid particles can protect fragile compounds and alter how they penetrate mucus or enter cells. Stimuli-responsive systems are being studied to release medicine in response to pH, enzymes, temperature or disease-associated signals, although laboratory performance does not automatically predict clinical benefit.
A local therapy for reflux injury may need broad coverage across a longer segment, while a focal neoplasm may require precise placement during endoscopy. For strictures, a drug-releasing biodegradable stent could potentially combine dilation with anti-scarring or anti-tumour activity, but the treatment must not interfere with healing or create an obstruction.
Patient behaviour also affects performance. Australian patients may take medicines during a busy commute in Sydney or Melbourne, or manage treatment around meals, coffee and work schedules. Instructions must be realistic: whether water is permitted, how long to remain upright and when food can be consumed may determine adherence as much as the formulation itself.
Promising results should be assessed through a sequence of in vitro testing, animal studies, pharmacokinetic analysis and controlled clinical trials. Important endpoints include mucosal drug concentration, residence time, symptom relief, healing on endoscopy and adverse events. Researchers must also compare local delivery with established proton pump inhibitors, endoscopic therapy, surgery or systemic oncology treatment.
In Australia, a medicine or combination product may require evaluation under the Therapeutic Goods Act and inclusion on the Australian Register of Therapeutic Goods before broad marketing. A novel device-drug combination can raise additional regulatory questions. Reimbursement through the Pharmaceutical Benefits Scheme is separate from approval, so a clinically useful product may still face access barriers.
Development teams can improve the relevance of their studies by planning for Australian clinical settings, including tertiary services in Brisbane, Perth, Adelaide and other major centres, as well as patients who travel from regional or remote communities. A product that requires frequent endoscopy may be less practical than one that can be administered during an existing appointment.
Useful priorities include:
The strongest candidates will probably be those that solve a defined clinical problem rather than simply use advanced nanotechnology. A local formulation should offer a measurable advantage over existing care, such as longer mucosal contact, fewer systemic effects, easier administration or improved treatment of a lesion that currently responds poorly.
Research communication also matters. Congress presentations, workshops and published abstracts can help clinicians, formulation scientists, gastroenterologists, surgeons and regulators identify shared safety requirements. For Australian implementation, early consultation with the TGA and a specialist gastroenterology service can clarify whether a proposed product is a medicine, a medical device or a combination product.
The next practical step is to select one target condition and prepare a comparative study measuring local drug exposure, residence time and patient usability against the current standard treatment.